Quiet strength for tough days - UCB’s Briviact steps out of Keppra’s shadow

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 05:51. Details in the imprint.

Briviact is one of those drugs that rarely make headlines, yet for people with focal seizures it can mean the difference between an anxious bus ride and a calm commute. The UCB medicine is designed to sit quietly in the background and keep electrical storms in the brain in check. Patients often describe days on a stable dose as simply "less unpredictable" - which is exactly the point.

Where Briviact fits in

In everyday practice, Briviact often appears when levetiracetam - better known under UCB’s own brand Keppra - does not quite hit the sweet spot between seizure control and tolerability. Neurologists then reach for Briviact as a kind of quieter cousin with a similar mechanism but a slightly different profile.

The active substance brivaracetam binds very selectively to the synaptic vesicle protein 2A, just like levetiracetam, but with higher affinity. That technical detail matters, because it allows the drug to modulate the release of neurotransmitters in overactive networks without sedating patients as heavily at comparable seizure control in many cases.

Daily life on the medicine

Talk to patients and the description is rarely dramatic. They describe mornings that start without the constant fear of a sudden focal jerk while brushing teeth, or the relief of getting through a supermarket queue without aura symptoms creeping in. That is the emotional core of Briviact’s promise.

Side effects are still present - dizziness, fatigue, sometimes mood swings - but many users and clinicians report that the drug can feel more "rounded" than classic levetiracetam in sensitive patients. Not everyone experiences that difference, and some switch back, yet the option itself creates breathing room in therapy planning.

Dosing and formats matter

UCB offers Briviact in several strengths and forms so that treatment can be tailored to a stubbornly individual disease. Film-coated tablets, oral solution and, in some regions, an injectable form for hospital settings allow smooth transitions from acute to maintenance therapy.

For families and caregivers, the oral solution can be a relief. Measuring a defined dose into a small glass of juice is often easier than splitting tablets for younger or older patients whose hands shake, or who struggle with swallowing in stressful moments.

Competition in epilepsy care

The anti-seizure market is crowded, with generics driving prices down and new mechanisms appearing from competitors. UCB itself plays on several boards at once, from Keppra and Briviact to pipeline projects that hope to tackle more complex epileptic syndromes and comorbidities.

Briviact therefore stands less as a lone hero and more as part of a therapy toolkit. For UCB that is strategic: the company wants to cover an entire treatment pathway, from first-line generics to specialized options for difficult courses, and to retain prescribing physicians inside its ecosystem.

What investors should note

For the balance sheet, Briviact is not the blockbuster that defines UCB’s fate, but it is an important pillar that supports the neurology franchise beyond Keppra’s patent cliff. Each incremental prescription cushions erosion from older brands and helps fund newer, riskier research projects.

All told, the product illustrates how the Belgian group tries to evolve from a single-hit epilepsy champion into a broader central nervous system specialist. Shares of UCB S.A. (BE0003739530) are listed on Euronext Brussels in euros.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.